亚博真人ag

HitGen Licenses Its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

CHENGDU, CHINA, November 10 -HitGen Inc. (HitGen, 688222.SH)announces it has entered into a collaboration and licensing agreement Read More+

HitGen to acquire Vernalis, a leader in structure-based drug discovery

CHENGDU, CHINA - HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. Read More+

HitGen and Almirall announce achievement of milestone in their strategic collaboration

Chengdu, China, August 26, 2020 HitGen Inc. (688222.SH) announced that the company has achieved a milestone in their strategic collaboration with Almirall to develop a novel class of drugs. Read More+

HitGen and Morphic Extend Drug Discovery Research Collaboration

Chengdu, China, July 6, 2020 – HitGen Inc. (HitGen, 688222.SH) announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. Read More+

HitGen and Evotec SE Enter Into Drug Discovery Research Collaboration

CHENGDU, China, June 8, 2020 -- HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with Evotec SE to identify small molecule leads against targets of interest to Evotec SE in the field of anti-infectives. Read More+

Oncodesign and HitGen announce a strategic partnership in Integrated Drug Discovery Services (IDDS)

Dijon (France) and Chengdu (China), May 25, 2020, 6:00pm (France) -ONCODESIGN (ALONC – FR0011766229) and HITGEN (688222.SH) today announced the start of a worldwide strategic alliance in Integrated Drug Discovery Services Read More+

Lipigon enters agreement with HitGen to develop drugs for cardiometabolic diseases

Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has entered an agreement with STAR listed (Shanghai market) company HitGen Inc. (”HitGen”). Read More+

HitGen and MTPC Enter Into License Agreement

Chengdu, China, April 8, 2020 HitGen Inc. (HitGen) announced today that HitGen and Mitsubishi Tanabe Pharma Corporation (MTPC) Read More+

HitGen’s New Generation of NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial

On 30th March 2020, HitGen Inc announces that its small-molecule tyrosine kinase inhibitor HG030 has obtained IND approval from the CDE (Center For Drug Evaluation) Read More+

HitGen and Kaken Enter Into License Agreement

Chengdu, China, March 11, 2020 HitGen Inc. (HitGen) announced today that HitGen and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs. This is the second licensing agreement. Read More+